San Francisco, CA (PRWEB) January 12, 2015
Genomic Expression to Present at the Biotech ShowCase Monday January 12th at 1:45 pm in San Francisco, where CEO, Gitte Pedersen will announce the latest developments.
Genomic Expression has made RNA-seq clinically applicable by reengineering sample prep and bioinformatics achieving a 10 fold reduction of cost and a 1000 fold reduction of complexity.
The company is leveraging it's technology with access to fully annotated biological samples in a single payer system that established electronic medical records a decade ago in a novel partnering model with diagnostic and drug discovery companies.
Genomic Expression closed it's first Dx deal, projecting revenue in 2015. Under the deal terms, the company will launch a novel cancer diagnostic test under exclusively in Scandinavia. The test utilizes next-generation sequencing to analyze known cancer genes involved in cancer initiation and progression. The information can be used directly by physicians to assist in the selection of effective treatment options
In addition a pipeline of beta testers have been established among big pharma and key academic centers.
About Genomic Expression
Genomic Expression’s mission is to develop diagnostics that save lives and make the delivery of healthcare more effective. The inconvenient truth is that only one out of 4 cancer treatments prolong life.
Genomic Expression is developing diagnostics using its proprietary sample preparation technologies for sequencing and access to biological samples in a novel partnership model.